J Med Microbiol NEW Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bagg, J.
Right arrow Articles by Brailsford, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagg, J.
Right arrow Articles by Brailsford, S.
Agricola
Right arrow Articles by Bagg, J.
Right arrow Articles by Brailsford, S.
J Med Microbiol 54 (2005), 959-964; DOI: 10.1099/jmm.0.45720-0
© 2005 Society for General Microbiology
ISSN 0022-2615

Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer

Jeremy Bagg1, M Petrina Sweeney1, Andrew N Davies2, Margaret S Jackson1 and Susan Brailsford3

1Infection and Immunity Section, Glasgow Dental Hospital and School, 378 Sauchiehall Street, Glasgow G2 3JZ, UK 2Department of Palliative Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK 3Department of Oral Microbiology, GKT Dental Institute, Floor 28, Guy's Tower, Guy's Hospital, London SE1 9RT, UK

Correspondence Jeremy Bagg j.bagg{at}dental.gla.ac.uk

Received April 27, 2004
Accepted June 27, 2005

The in vitro activity of voriconazole was compared with those of fluconazole and itraconazole against 270 clinical isolates of yeasts from the mouths of patients receiving palliative care for advanced cancer. A broth micro-dilution assay as described by the National Committee for Clinical Laboratory Standards was employed for determination of MICs. Of the 270 isolates, 206 (76 %) were fluconazole sensitive and 64 were fluconazole resistant. Voriconazole showed more potent activity than either fluconazole or itraconazole, including against some isolates resistant to both fluconazole and itraconazole. However, for fluconazole-resistant isolates, the MICs of itraconazole and voriconazole were proportionally higher than for the fluconazole-susceptible isolates, suggesting cross-resistance. Voriconazole may be a useful additional agent for the management of oral fungal infections caused by strains resistant to fluconazole and itraconazole, but susceptibility cannot be assumed and in vitro MIC determination is recommended prior to its use.

Abbreviation: NCCLS, National Committee for Clinical Laboratory Standards.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2005 Society for General Microbiology.